Building a Platform for Innovation and Precision
As Director of the Computer-aided Biology and Platform Proteomics Groups, Andre leads teams that integrate automation and high-throughput screening to enhance analytical capabilities. His Computer-Aided Biology Group focuses on implementing cutting-edge technologies, while the Platform Proteomics Group manages OXB’s mass spectrometry facilities, enabling deep analysis of cellular and vector proteins. These groups play a crucial role in characterising products for clients, ultimately accelerating the development and commercialisation of transformative therapies.
“Our goal is to help clients bring therapies to patients faster by combining innovative technology with rigorous analytics.”
Innovative Cell and Gene Therapy Solutions
OXB’s commitment to pioneering lentiviral vector technology has led to innovations such as fourth generation lentiviral vectors – the TetraVecta™ system – and Producer Cell Lines with the LentiStable™ technology. These developments, coupled with enhanced bioprocessing capabilities, allow OXB to increase vector yields and purity. Andre highlights recent improvements through U1 snRNA and I3A, designed to boost titres, demonstrating the power of targeted bioprocess enhancements.
Digital transformation plays a key role as well, with OXB offering Design of Experiment (DOE) services supported by automated systems, allowing for a more efficient analysis of vectors for quality control and regulatory approval.
Transforming Analytics with Advanced Automation
The integration of automation has been pivotal in increasing throughput and reducing timelines in analytical processes. Andre’s team has introduced automated systems that streamline assay setup for processes like PCR, Tissue Culture, and mass spectrometry. This approach enhances both the efficiency and robustness of analytical workflows, allowing OXB to release products to clients faster while maintaining rigorous quality and safety standards.
“Automation has transformed how we perform analytics at OXB, enabling 24/7 operation and increasing both our capacity and precision.”
Tackling Client Challenges with Technology
Automation at OXB doesn’t just increase output; it addresses specific client needs by improving the accuracy and reproducibility of assays. By introducing liquid handlers for sample preparation and Electronic Lab Notebooks (ELNs) across R&D and Process Development, the team has streamlined data capture and visualization. This holistic approach to digital transformation enables OXB to gain deeper insights into processes, ultimately enhancing client outcomes.
Conclusion
OXB’s focus on combining advanced technology with rigorous analytical methods is creating new possibilities in the field of cell and gene therapy. Under the guidance of leaders like Andre Raposo, the company continues to innovate and deliver impactful solutions that are transforming the healthcare landscape.
If you’re curious about how advanced automation and digital platforms can reshape the future of gene therapy, join us for our upcoming webinar on Monday 9th December at 16:00 GMT / 17:00 CET. Register for the webinar!
About Dr. Andre Raposo
Dr. Raposo leads a team of scientists advancing cell and gene therapy research through computer-aided biology and high-throughput automation. He has expertise in technology development, upstream process development, DoE strategies, analytical development, robotics, and regulatory compliance. Previously, he worked at GSK’s Transduction Sciences CGT Platform CMC. Dr. Raposo earned his PhD from the University of Oxford and conducted postdoctoral research on HIV replication and persistence at the University of California, San Francisco, and George Washington University.